Indication: Pulmonary Hypertension
A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients with Pulmonary Hypertension due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Sub-indication: Pulmonary Arterial Hypertension
Study Type: Drug Study
Principal Investigator: John McConnell, M.D.Norton Pulmonary Specialists
Sponsor: Sponsor: UNITED THERAPEUTICS CORPORATION
Learn more at ClinicalTrials.gov
Email for more information: npsresearch@nortonhealthcare.org